prasugrel   Click here for help

GtoPdb Ligand ID: 7562

Synonyms: CS-747 | Effient® | Efient®
Approved drug
prasugrel is an approved drug (FDA and EMA (2009))
Compound class: Synthetic organic
Comment: This drug is metabolised to its active metabolite R-138727.
Marketed formulations may contain prasugrel hydrochloride (PubChem CID 10158453).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: prasugrel

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 74.85
Molecular weight 373.11
XLogP 2.2
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC(=O)Oc1sc2c(c1)CN(CC2)C(c1ccccc1F)C(=O)C1CC1
Isomeric SMILES CC(=O)Oc1sc2c(c1)CN(CC2)C(c1ccccc1F)C(=O)C1CC1
InChI InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
No information available.
Summary of Clinical Use Click here for help
Prasugrel is used to prevent to prevent atherothrombotic events in patients with acute coronary syndrome (eg unstable angina, heart attack) undergoing percutaneous coronary intervention. It may also be used in patients with certain disorders of the heart or blood vessels.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
R-138727 is an antagonist of the P2Y12 receptor, which is an adenosine diphosphate (ADP) receptor expressed on platelets. ADP-induced activation of P2Y12 causes platelet aggregation and promotes blood clot formation. Antagonism of ADP binding inhibits these effects.
External links Click here for help